| Project/Area Number |
26461936
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | Hokkaido University |
|---|
Principal Investigator |
Hiraoka Kei 北海道大学, 医学研究科, 客員研究員 (10719587)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
平野 聡 北海道大学, 医学研究科, 教授 (50322813)
土川 貴裕 北海道大学, 大学病院, 講師 (50507572)
七戸 俊明 北海道大学, 医学研究科, 准教授 (70374353)
中村 透 北海道大学, 医学研究科, 助教 (70645796)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Keywords | レトロウイルス / プロドラッグ / 膵癌 / 遺伝子治療 / ウイルスベクター |
|---|
| Outline of Final Research Achievements |
In the present study, we are developing a retroviral replicating vector (RRV)-mediated prodrug activator gene therapy as a new therapeutic approach for pancreatic ductal adenocarcinoma. With this system, the prodrug (antifungal drug) is converted to the anticancer drug within RRV infected cells. In pancreatic cancer preclinical models, high levels of transduction were achieved and systemic administration of 5-FC resulted in significant inhibition of tumor growth.
|
